GENFIT Releases Impactful CSR Performance Report
Company Announcements

GENFIT Releases Impactful CSR Performance Report

Genfit (GNFT) has released an update.

GENFIT, a leader in liver disease therapeutics, has published its 2024 Extra-Financial Performance Report, highlighting its commitment to social responsibility and its alignment with new European non-financial disclosure standards. The company’s CSR efforts have been recognized with several awards, and it continues to focus on creating long-term value through sustainable practices. GENFIT’s robust R&D portfolio targets rare and life-threatening liver diseases, with a significant focus on Acute-on-Chronic Liver Failure (ACLF) and other serious conditions.

For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskGenfit’s Iqirvo Wins EU Approval for Liver Condition
TipRanks Auto-Generated NewsdeskGENFIT SA Showcases Robust 2024 Financial Health
TipRanks Auto-Generated NewsdeskGenfit SA Expands R&D, Gains FDA Approval
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App